50,906 Shares in NeoGenomics, Inc. (NASDAQ:NEO) Bought by Raymond James Financial Inc.

Raymond James Financial Inc. bought a new stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 50,906 shares of the medical research company’s stock, valued at approximately $839,000.

Several other hedge funds have also bought and sold shares of NEO. SBI Securities Co. Ltd. bought a new position in shares of NeoGenomics during the 4th quarter valued at approximately $26,000. Versant Capital Management Inc lifted its holdings in NeoGenomics by 174.9% during the fourth quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 1,142 shares in the last quarter. Quarry LP bought a new position in shares of NeoGenomics in the third quarter worth approximately $40,000. Smartleaf Asset Management LLC increased its stake in shares of NeoGenomics by 203.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 4,156 shares of the medical research company’s stock worth $70,000 after purchasing an additional 2,787 shares in the last quarter. Finally, Blue Trust Inc. raised its position in shares of NeoGenomics by 33.2% during the 4th quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company’s stock valued at $73,000 after purchasing an additional 1,103 shares during the period. Institutional investors own 98.50% of the company’s stock.

Analyst Ratings Changes

NEO has been the subject of several recent analyst reports. Piper Sandler dropped their target price on shares of NeoGenomics from $21.00 to $18.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Bank of America dropped their price objective on NeoGenomics from $19.00 to $16.00 and set a “neutral” rating for the company in a research note on Wednesday, February 19th. The Goldman Sachs Group lowered their price target on NeoGenomics from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. Needham & Company LLC cut their price objective on shares of NeoGenomics from $19.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, February 19th. Finally, Benchmark downgraded shares of NeoGenomics from a “buy” rating to a “hold” rating in a report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $19.60.

NeoGenomics Trading Up 0.7 %

NEO stock opened at $8.78 on Friday. The firm has a fifty day moving average price of $11.39 and a 200 day moving average price of $14.12. NeoGenomics, Inc. has a fifty-two week low of $8.27 and a fifty-two week high of $19.12. The firm has a market cap of $1.13 billion, a PE ratio of -14.16 and a beta of 1.28. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.91 and a current ratio of 1.98.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Tuesday, February 18th. The medical research company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.05). The business had revenue of $172.00 million during the quarter, compared to analysts’ expectations of $173.40 million. NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. Sell-side analysts anticipate that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.